Research programme: adenosine receptor antagonists - Merck/ Domain TherapeuticsAlternative Names: immuno oncology therapeutics - Merck/Domain Therapeutics
Latest Information Update: 08 Feb 2017
At a glance
- Originator Domain Therapeutics
- Developer Domain Therapeutics; Merck KGaA
- Class Antineoplastics; Immunotherapies; Small molecules
- Mechanism of Action Purinergic P1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Cancer